Literature DB >> 3102323

Comparative trial of sodium cromoglycate enemas with prednisolone enemas in the treatment of ulcerative colitis.

R H Grace, A E Gent, M D Hellier.   

Abstract

A double blind multicentre study comparing sodium cromoglycate (600 mg/100 ml) by enema with prednisolone (20 mg/100 ml) by enema is reported. The study was conducted over a nine week period in the treatment of 70 patients with ulcerative colitis. Analysis of symptoms showed significant decreases in scores for patients in both groups, both at four and eight weeks; the only difference between the two groups was a significantly greater improvement in the reduction of rectal bleeding after four weeks in the prednisolone group. On sigmoidoscopy, both treatment groups showed a highly significant improvement after four and eight weeks with no significant differences being seen between the groups. Histology of the rectal biopsies showed a significant improvement in the inflammation of the mucosa for both treatment groups after four and eight weeks with no differences being observed between the groups. There were no significant changes in eosinophils from baseline and no difference between the groups at four and eight weeks.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102323      PMCID: PMC1432725          DOI: 10.1136/gut.28.1.88

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  8 in total

1.  Controlled trial of disodium cromoglycate in chronic persistent ulcerative colitis.

Authors:  N A Buckell; S R Gould; D W Day; J E Lennard-Jones; A M Edwards
Journal:  Gut       Date:  1978-12       Impact factor: 23.059

2.  Treatment of ulcerative colitis with oral disodium cromoglycate. A double-blind controlled trial.

Authors:  V Mani; G Lloyd; F H Green; H Fox; L A Turnberg
Journal:  Lancet       Date:  1976-02-28       Impact factor: 79.321

3.  Comparative trial of sulphasalazine and oral sodium cromoglycate in the maintenance of remission in ulcerative colitis.

Authors:  M W Dronfield; M J Langman
Journal:  Gut       Date:  1978-12       Impact factor: 23.059

4.  Plasma prednisolone levels and adrenocortical responsiveness after administration of prednisolone-21-phosphate as a retention enema.

Authors:  D A Lee; G M Taylor; V H James; G Walker
Journal:  Gut       Date:  1979-05       Impact factor: 23.059

5.  Disodium cromoglycate in the treatment of chronic proctitis.

Authors:  R V Heatley; B J Calcraft; J Rhodes; E Owen; B K Evans
Journal:  Gut       Date:  1975-07       Impact factor: 23.059

6.  Comparison of disodium cromoglycate and sulphasalazine as maintenance therapy for ulcerative colitis.

Authors:  C P Willoughby; M F Heyworth; J Piris; S C Truelove
Journal:  Lancet       Date:  1979-01-20       Impact factor: 79.321

7.  Disodium cromoglycate in the treatment of ulcerative colitis and Crohn's disease.

Authors:  V Binder; L Elsborg; J Greibe; C Hendriksen; L Høj; K B Jensen; E Kristensen; J R Madsen; B Marner; P Riis; L Willumsen
Journal:  Gut       Date:  1981-01       Impact factor: 23.059

8.  Rectally administered prednisolone--evidence for a predominantly local action.

Authors:  D A Lee; M Taylor; V H James; G Walker
Journal:  Gut       Date:  1980-03       Impact factor: 23.059

  8 in total
  4 in total

1.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.

Authors:  J K Marshall; E J Irvine
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

Review 2.  Inflammatory bowel disease.

Authors:  G M Van Rosendaal
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

Review 3.  New developments in the pharmacotherapy of inflammatory bowel disease.

Authors:  J W Harting
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

4.  Anti-allergic cromones inhibit histamine and eicosanoid release from activated human and murine mast cells by releasing Annexin A1.

Authors:  Samia Yazid; Ajantha Sinniah; Egle Solito; Virginia Calder; Rod J Flower
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.